40 results about "Polyinosinic:polycytidylic acid" patented technology

The invention provides a preparation method of polyinosinic-polycytidylic acid dry powder. The method comprises the following steps: (1) respectively dissolving polyinosinic acid and polycytidysic acid in a phosphate buffer solution, mixing the solution, adding a stabilizer, uniformly mixing the stabilizer and the solution, and performing heat preservation on the mixture at the temperature of 40-100DEG C; (2) naturally cooling the reaction liquid obtained in the step (1), mixing the reaction liquid with an organic solvent, standing for precipitating, and drying the precipitate, thereby obtaining the polyinosinic-polycytidylic acid dry powder. The preparation method has the beneficial effects that the prepared polyinosinic-polycytidylic acid dry powder has a complete double-helix structural features and physiological activity, the quality and the stability are better than those of the polyinosinic-polycytidylic acid at a solution state, a stronger enzymolysis-resisting performance can be achieved compared with the bare polyinosinic-polycytidylic acid after entering a living body, so that the curative effect can be enhanced. The polyinosinic-polycytidylic acid is purified in the process for making the polyinosinic-polycytidylic acid solution into the dry powder, a plurality of small-molecular-weight substances and impurities can be removed, the toxic and side effects can be reduced, and the quality of the polyinosinic-polycytidylic acid can be improved.

The invention discloses a herpes zoster vaccine, and a preparation method and an application thereof, and belongs to the field of vaccines. The herpes zoster vaccine is provided against the problem ofhigh safety risk of existing herpes zoster vaccines, and an adjuvant used by the herpes zoster vaccine is Poly (I:C). The Poly(I:C) is called polyinosinic-polycytidylic acid for short, and is double-stranded RNA, and the safety of the Poly(I:C) is confirmed during large-scale clinical application. The Poly(I:C) is a high-efficiency interferon inducer, can produce an immune reaction like viral infection in vivo, and can induce CD4<+> and CD8<+> T cells and enhance cellular and humoral immune responses.

The invention relates to the field of biological medicine, in particular to an application of poly inosine-cytidine, imiquimod and gardiquimod in constructing a virus immunity mouse model. The inventor of the invention employs the mouse model and forms an antivirus immune state by using poly inosine-cytidine, imiquimod and gardiquimod; an experiment mouse administered with poly inosine-cytidine is found to appear lung bacterium clearance impairment; in addition, poly inosine-cytidine is found to be capable of mediating IFNI expression; and finally, IFNI can induce a defense mechanism of a lung against gram positive pathogenic bacteria.

The invention relates to the technical field of immunization, in particular to a polyinosinic: polycytidylic acid copolymer (Poly I: C). The polyinosinic: polycytidylic acid copolymer is a ligand of atype-3 Toll-like receptor in an animal body, can mediate a series of immune reactions of the body after TLR-3 is activated, and has a good promoting effect on specific immunity and non-specific immunity of the body. Compared with a control group, DC-CIK induced by the polyinosinic: polycytidylic acid copolymer has higher proliferation, high differentiation (especially CD3+CD4-CD8+, CTL) and hightumor killing activity. The autologous efficient DC-CIK induced by the polyinosinic: polycytidylic acid copolymer and other immune cells are applied to treatment of clinical tumor patients. The polyinosinic: polycytidylic acid copolymer aims to recover or improve the immune function of the tumor patients, and the immune system of the body is improved to kill and inhibit proliferation of tumor cells. The tumor cell load is reduced, tiny residual lesions are removed, or the proliferation mode of residual tumor/cancer cells is obviously inhibited, factors such as relapse and metastasis are eliminated, the cure possibility is increased, the survival time is prolonged, and the life quality is improved. Therefore, the purpose of treating tumors/cancers is achieved.

The invention relates to the field of cell culture and virus and tumor resistance of immune cells, and particularly discloses a human dendritic cell induction method and composition for virus and tumor resistance. The human dendritic cell induction composition comprises a mature human dendritic cell induction composition and an immature human dendritic cell induction composition, wherein the mature human dendritic cell induction composition consists of poly I: C and recombinant human interleukin 1 beta (IL-1beta), and the immature human dendritic cell induction composition consists of a granulocyte-macrophage colony stimulating factor (GM-CSF), recombinant human interleukin 4 (IL-4) and interferon beta (IFN-beta). The human dendritic cell induction method based on the human dendritic cell induction composition is used for inducing and culturing for 3 days to obtain a DC which is short in culture period, strong in aggregation, strong in function of inducing allogenic initial CD4 + T cells and CD8 + T cells and capable of inducing antigen-specific CD8 + T cells; the culture period can be greatly shortened by utilizing the method, and the highly-functional DC is obtained and is used as an early-stage basis of virus resistance and tumor resistance of clinical cell vaccines.

The invention belongs to the technical field of veterinary biological products, and concretely relates to a diluent used for an inactive porcine parvovirus vaccine. Every 1000 ml of a phosphate buffer solution with the pH value of 7 includes 1-5 g of honeysuckle flower and Weeping Forsythia extract, 5-10 g of wolfberry fruit polysaccharides, 20-80 mg of astragaloside II and 1-5 g of polyinosinic-polycytidylic acid. The diluent used for the inactive porcine parvovirus vaccine has the advantages of convenience in production, low cost, convenience and safety in use, reduction of the difference among different batches of vaccines, and improvement of the integral immunizing effect of the vaccine.

The invention discloses a polyinosinic-polycytidylic acid injection and a method for lowering toxins in the polyinosinic-polycytidylic acid injection. Positive lipidosome is added in the polyinosinic-polycytidylic acid injection. The method comprises the steps: polyinosinic acid and polycytidylic acid are dissolved and mixed according to the set proportion, and a double-chain polyinosinic acid-polycytidylic acid polymer solution is formed; the positive lipidosome is added into the double-chain polyinosinic acid-polycytidylic acid polymer solution, thus a to-be-treated solution is obtained, andthe to-be-treated solution is magnetically stirred; and then the PH value of the to-be-treated solution is regulated, the to-be-treated solution subjected to PH value regulating is filtered, and thusthe polyinosinic-polycytidylic acid injection is obtained. According to the polyinosinic-polycytidylic acid injection and the method for lowering the toxins in the polyinosinic-polycytidylic acid injection, the toxins in the polyinosinic-polycytidylic acid injection are effectively lowered, safety and effectiveness of clinical medication are facilitated, and using and popularization are facilitated.

The present invention concerns a composition comprising micro particles of polyinosinic-polycytidylic acid (Poly (I:C)) and a carrier polymer selected from starch, alginate, blanose or DPPC (dipalmitoylphosphatidylcholine) for use in preventing and/or treating viral infections of the upper respiratory tract or the common cold and a device, preferably a nasal delivery system, comprising said composition for use by a patient in need to prevent and/or treat infections or the common cold.

The invention relates to an application of a compound acetylshikonin in preparation of a medicine for resisting lung inflammatory factor storm, namely an inhibition effect of acetylshikonin on mouse acute lung injury and inflammatory factor storm induced by polyinosinic-cytidylic acid and SARS-CoV-2 spinous process protein. The compound acetylshikonin can inhibit inflammatory factors induced by polyinosinic-cytidylic acid and SARS-CoV-2 spinous process protein, obviously inhibits expression of interleukin IL-6 in inflammatory reaction, and can be further applied to research and development of drugs for treating or preventing lung inflammation. The acetylshikonin is suitable for treating lung inflammatory factor storm and acute lung injury caused by viral pneumonia, bacterial pneumonia, mycoplasma pneumonia and the like.

The invention relates to the field of biological medicine, and especially relates to polyinosinic-polycytidylic acid having long-term unfavorable influence on an anti-bacterial defense mechanism. According to the invention, after bacteria infection, influence of polyinosinic-polycytidylic acid administration on bacteria clearance and animal lung bacteria amount of polyinosinic-polycytidylic acid administration are obviously increased, polyinosinic-polycytidylic acid enhances the susceptibility of bacteria on lung tissue, a proportional relation of damage degree on bacteria removing force and continuous time of the proportional relation administration is established, and the polyinosinic-polycytidylic acid has influence on anaphase bacteria removing force. The long-term unfavorable influence of polyinosinic-polycytidylic acid on the lung antibiosis defense mechanism is confirmed.

The invention discloses a tumor vaccine in mice and a preparation method thereof. The vaccine contains saccharomyces cerevisiae shell glucan GP, adjuvant polyinosinic-polycytidylic acid Poly(I:C) andpolypeptide M30, which are bonded in a mass ratio of 1:(20-25):(10-12) respectively. The tumor vaccine in mice and the preparation method thereof can overcome the technical defect that the combinationof an MHC class I molecule and short peptides cannot activate CD4+T cells in the prior art, can achieve the aim of activating the CD4+T cells by introducing the specific tumor adjuvant for the firsttime, so that the tumor vaccine in mice has a function of inhibiting tumor growth; and a new thought and foundation are provided to researches and development of vaccines for treating human tumors.

The invention discloses an application of polyinosinic acid combined with an anti-CD47 antibody in tumor treatment, which can promote the innate immune function of macrophages so as to improve the activation performance of the anti-CD47 antibody, promote the macrophages to kill tumor cells and improve the response rate of tumor patients to the anti-CD47 antibody. Meanwhile, when the polyinosinic acid is combined with the anti-CD47 antibody to treat tumors, adverse reactions such as anemia and the like caused in the treatment process can be remarkably reduced, and the life quality of a patientand the compliance in the treatment process are improved; more importantly, solid tumors including colon cancer can be treated by combining the Poly I: C immunologic adjuvant with the anti-CD47 antibody for immunotherapy, so that the restriction that the anti-CD47 antibody is difficult to realize an effective treatment effect on the solid tumors in the prior art is broken through; a new research direction is provided for immunotherapy and colon cancer treatment in the prior art, and development of the field of tumor treatment is promoted.

The invention belongs to the field of screening of pig molecular markers and relates to an SNP (Single Nucleotide Polymorphism) molecular marker capable of influencing the quantity of red blood cellsof pigs. The molecular marker is especially correlated with an SNP molecular marker of a red blood cell quantity property of 80-day-old pigs and is cloned from a gene with a registration number of MARC0065518; a gene chip technology is used for carrying out typing screening on the gene to obtain the molecular marker which is correlated with the quantity of the red blood cells of the pigs infectedwith polyinosinic-polycytidylic acid, and a nucleotide sequence is shown as SEQ ID NO: 1; allelic mutation of one T/C occurs on a 101st basic group of the sequence; the SEQ ID NO: 1 sequence has polymorphism due to the mutation. When 101st basic nucleotide on the SEQ ID NO: 1 is C, the pigs have higher red blood cell quantity. The invention discloses a method for screening the molecular marker andapplication of correlation analysis of the molecular marker. The invention provides the novel SNP molecular marker for immunological properties of the pigs, especially marker-assisted selection of the red blood cell quantity.

The invention discloses an immunopotentiator for a swine fever live vaccine. The immunopotentiator comprises liquid containing corynebacterium parvum (CP) immune particles and solvent,the corynebacterium parvum particle liquid is mainly composed of Tween-80,astragalus polysaccharide,poly I:C (Poly I:C),ethylene diamine tetraacetic acid,manganese gluconate,potassium iodide and corynebacterium parvum preparation (CPP) according to suitable proportions and medicine compatibility. Compared with the prior art,the prepared immunopotentiator for the swine fever live vaccine can effectively inhibit construction and re-activation of swine fever virus latent infection,generate short-term immunity through induction,improve the immune effect of the swine fever vaccine,prolong the immune duration period,effectively avoid the latent infection of the swine fever virus,provide guarantee for prevention and eradication of the swine fever,be widely applied to prevention and treatment of swine fever in pig farms,and improve the economic benefits of the pig farms.

The invention provides application of polyinosinic acid in preparation of a biological agent for improving the response level of HBsAg positive mother infant hepatitis B vaccines, and belongs to the technical field of biological agents. The invention discloses application of polyinosinic acid in preparation of a biological agent for improving the response level of HBsAg positive mother infant hepatitis B vaccines. HBeAg of an HBsAg positive mother inhibits a TLR3 signal channel, and placenta immunity is influenced to reduce the immune level of an infant, so that no/weak response of a hepatitis B vaccine is caused. The polyinosinic acid activates a trophoblast cell TLR3 signal channel to increase secretion of IL-2, increase the proportion of CD4 + T cells in PBMC, reduce the proportion of Treg cells and improve the immune level of the body, and rHBsAg stimulation can improve the expression quantity of IL-6 and the proportion of myelodendritic cells (mDC), reduce the expression of IL-10 and improve the anti-HBs level.Therefore, therefore the polyinosinic acid is beneficial to improving the response level of the body to the hepatitis B vaccines.

NK cells are obtained by administering a Toll-like receptor ligand such as polyinosinic-polycytidylic acid into the peritoneal cavity of an animal to which lactoferrin has been administered to proliferate NK cells in the peritoneal cavity and collecting NK cells from the peritoneal cavity.

The invention especially relates to beneficial influence of activation of TLR3 and RIG-I signaling pathways on bacterium-elimination barrier effect caused by polyinosinic-polycytidylic acid, belonging to the field of biological medicine. According to the invention, a virus-immune mouse model is simulated, and TLR3-gene-knocked mice, Cardif-gene-knocked mice and TLR3-and-Cardif-gene-knocked mice are dosed with polyinosinic-polycytidylic acid; and final results prove that activation of the TLR3 and RIG-I signaling pathways exerts effect in alleviating bacterium-elimination barrier effect on the lung of a host caused by polyinosinic-polycytidylic acid.